1. How the Latest Data in MDD Can Guide Treatment Decisions:

2. A Look at Cognition and Depressive Symptomatology

3. Cognitive Performance in Patients With MDD Treated With Vortioxetine Compared With Escitalopram and Venlafaxine Study Design and Participants

4. Cognitive Performance in Patients With MDD Treated With Vortioxetine Compared With Escitalopram and Venlafaxine Results

5. Functional Recovery in Patients With MDD -- the Role of Cognitive Symptoms in Clinical Practice Study Design

6. Functional Recovery in Patients With MDD -- the Role of Cognitive Symptoms in Clinical Practice Results

7. Functional Recovery in Patients With MDD -- the Role of Cognitive Symptoms in Clinical Practice Conclusions

8. 30-Day Remission Rates in Severe PPD -- Primary and Secondary Endpoints From a Phase 2 Trial of Brexanolone Study Design and Participants

9. 30-Day Remission Rates in Severe PPD -- Primary and Secondary Endpoints From a Phase 2 Trial of Brexanolone Results

10. Treating Cognitive Dysfunction in MDD

11. Cognitive Performance and 12-Month Clinical Outcome in FED

12. Effects of Vortioxetine on Composite Scores Across Objective Cognitive Tests

13. Effects of Vortioxetine on Composite Scores Across Objective Cognitive Tests: Results

14. Subjective and Objective Cognitive Side Effects of ECT: A Pilot Study

15. An Evaluation of Depression Severity, Cognition, Functioning, and Well-Being

16. Depression Severity and Cognitive Symptoms Are Independent Predictors of Functioning in Patients With MDD

17. Depression Severity and Cognitive Symptoms Are Independent Predictors of Functioning in Patients With MDD Findings

18. The Effect of Cognition on the Well-Being of Patients With Major Depression

19. The Effect of Cognition on the Well-Being of Patients With Major Depression Findings

20. Key Points From the Studies

21. A Lively Debate and THINC-it

22. Debate Topic: What to Do When Patients Have Inadequate Response to First-Line Antidepressants

23. Key Points of the Debate

24. THINC-it

25. THINC-it Quality Survey Results

26. Adjunctive Strategies in MDD

27. FORWARD 5 -- a Study of a Sublingual Buprenorphine/Samidorphan Combination

28. FORWARD 5 -- a Study of a Sublingual Buprenorphine/Samidorphan Combination Study Design

29. FORWARD 5 -- a Study of a Sublingual Buprenorphine/Samidorphan Combination Results

30. Efficacy and Safety of Flexibly Dosed Brexpiprazole for the Adjunctive Treatment of MDD

31. Efficacy and Safety of Flexibly Dosed Brexpiprazole for the Adjunctive Treatment of MDD Study Design

32. Efficacy and Safety of Flexibly Dosed Brexpiprazole for the Adjunctive Treatment of MDD Results

33. Abbreviations

34. Abbreviations (cont)

35. Abbreviations (cont)

36. Abbreviations (cont)